195 related articles for article (PubMed ID: 38071078)
1. [Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review].
Fang S; Wang G; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1890-1893. PubMed ID: 38071078
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
3. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.
Sarangi P; Kumar N; Sambasivan R; Ramalingam S; Amit S; Chandra D; Jayandharan GR
Thromb Res; 2024 Jun; 238():151-160. PubMed ID: 38718473
[TBL] [Abstract][Full Text] [Related]
4. In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia.
Lee JH; Han JP
Mol Diagn Ther; 2024 May; 28(3):239-248. PubMed ID: 38538969
[TBL] [Abstract][Full Text] [Related]
5. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
6. [Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology].
Bao LW; Zhou YY; Zeng FY
Yi Chuan; 2020 Oct; 42(10):949-964. PubMed ID: 33229321
[TBL] [Abstract][Full Text] [Related]
7. What´s new in Gene Therapy of Hemophilia.
Rodriguez-Merchan EC
Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
[TBL] [Abstract][Full Text] [Related]
8. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.
Stephens CJ; Lauron EJ; Kashentseva E; Lu ZH; Yokoyama WM; Curiel DT
J Control Release; 2019 Mar; 298():128-141. PubMed ID: 30771412
[TBL] [Abstract][Full Text] [Related]
9. Adeno-Associated Virus Gene Therapy for Hemophilia.
Samelson-Jones BJ; George LA
Annu Rev Med; 2023 Jan; 74():231-247. PubMed ID: 36103998
[TBL] [Abstract][Full Text] [Related]
10. Current and future prospects for hemophilia gene therapy.
Ward P; Walsh CE
Expert Rev Hematol; 2016 Jul; 9(7):649-59. PubMed ID: 27153210
[TBL] [Abstract][Full Text] [Related]
11. Gene Therapy Approaches for the Treatment of Hemophilia B.
Soroka AB; Feoktistova SG; Mityaeva ON; Volchkov PY
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445943
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
Guan Y; Ma Y; Li Q; Sun Z; Ma L; Wu L; Wang L; Zeng L; Shao Y; Chen Y; Ma N; Lu W; Hu K; Han H; Yu Y; Huang Y; Liu M; Li D
EMBO Mol Med; 2016 May; 8(5):477-88. PubMed ID: 26964564
[TBL] [Abstract][Full Text] [Related]
13. Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
Ohmori T
Int J Hematol; 2020 Jan; 111(1):31-41. PubMed ID: 30083852
[TBL] [Abstract][Full Text] [Related]
14. Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response.
He X; Zhang Z; Xue J; Wang Y; Zhang S; Wei J; Zhang C; Wang J; Urip BA; Ngan CC; Sun J; Li Y; Lu Z; Zhao H; Pei D; Li CK; Feng B
Nat Commun; 2022 Nov; 13(1):7275. PubMed ID: 36434000
[TBL] [Abstract][Full Text] [Related]
15. Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.
Ma Y; Sun W; Zhao L; Yao M; Wu C; Su P; Yang L; Wang G
Stem Cell Res Ther; 2022 Jul; 13(1):353. PubMed ID: 35883203
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs.
Chen J; An B; Yu B; Peng X; Yuan H; Yang Q; Chen X; Yu T; Wang L; Zhang X; Wang H; Zou X; Pang D; Ouyang H; Tang X
Haematologica; 2021 Mar; 106(3):829-837. PubMed ID: 31974191
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.
Chen H; Shi M; Gilam A; Zheng Q; Zhang Y; Afrikanova I; Li J; Gluzman Z; Jiang R; Kong LJ; Chen-Tsai RY
Sci Rep; 2019 Nov; 9(1):16838. PubMed ID: 31727959
[TBL] [Abstract][Full Text] [Related]
19. Application of Gene Therapy in Hemophilia.
Hu YF; Fang YH; Lai YR; Feng XQ; Xu SQ
Curr Med Sci; 2022 Oct; 42(5):925-931. PubMed ID: 36260269
[TBL] [Abstract][Full Text] [Related]
20. Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro.
Zhao L; Fang S; Ma Y; Ren J; Hao L; Wang L; Yang J; Lu X; Yang L; Wang G
Gene; 2024 Feb; 896():148038. PubMed ID: 38036077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
